bYoRNA
Bordeaux
About bYoRNA
bYoRNA is a French biotechnology company specializing in the cost-efficient, scalable bioproduction of high-quality therapeutic messenger RNA (mRNA) using engineered eukaryotic cells, particularly recombinant yeast. Their disruptive platform enables the production of long, humanized mRNA with lower immunogenicity and higher integrity compared to traditional in vitro enzymatic synthesis. This technology aims to mass produce mRNA for gene therapies, cancer vaccines, and infectious disease vaccines at a fraction of current costs, making mRNA therapeutics more accessible globally.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Total funding: $1.8M
- Funding stage: Seed
- Last round: Pre-Seed (Jul 2025)
- Website: byorna.bio
Industries & Categories
Biopharma, Biotechnology, Industrial Engineering
Social Profiles
Canonical: https://fsome.com/organization/byorna-16715 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.